Pfizer nabs China obesity drug rights in $495 million deal

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Pfizer in diabetes drug deal with Sciwind Biosciences

SHANGHAI, Feb 24 (Reuters) - Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ...

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...
Labiotech.eu

Pfizer’s strategy: how the company is evolving after its COVID success

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma ...

Pfizer ponders Viagra lessons to chart first obesity drug launch

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity ...
Fierce Biotech

After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.
WTVD

Pfizer to raise drug prices beginning in January

Months after it agreed to hold off on raising prices following heavy pressure from President Trump, Pfizer now says it will increase the prices of 41 drugs in January. The pharmaceutical giant says ...

Understanding Blockbuster Drugs: Definition and Role in Healthcare

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...